<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04507321</url>
  </required_header>
  <id_info>
    <org_study_id>213051</org_study_id>
    <secondary_id>2019-004444-30</secondary_id>
    <nct_id>NCT04507321</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254</brief_title>
  <official_title>A Two-period Study in Healthy Male Participants to Determine the Pharmacokinetics, Balance/Excretion, and Metabolism of [14C]-GSK3640254 Following a Single Intravenous Radiolabeled Microtracer Dose (Concomitant With a Non-radiolabeled Oral Dose) and a Single Oral Radiolabeled Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-center, single group, non-randomized, two-period, single&#xD;
      sequence, mass balance study which will enroll 6 healthy male participants. This study will&#xD;
      assess the pharmacokinetics, balance/excretion, and metabolism of GSK3640254 in humans using&#xD;
      [14C]-radiolabeled drug substance administered as an intravenous (IV) infusion and via the&#xD;
      oral route. The study will also provide an assessment of GSK3640254 absorption, metabolism&#xD;
      and excretion following administration of a [14C]-radiolabeled oral suspension. Each&#xD;
      participant will be involved in the study for up to 10 weeks which will include a screening&#xD;
      period, two treatment periods (treatment Periods 1 and 2) separated by a washout of at least&#xD;
      13 days between oral doses, and a follow-up visit 7-14 days after the last assessment in&#xD;
      treatment Period 2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Actual">November 23, 2020</completion_date>
  <primary_completion_date type="Actual">November 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants will receive non-radiolabeled GSK3640254 oral tablets concomitantly with radiolabeled [14C]-GSK3640254 administered as an IV infusion in treatment Period 1 and radiolabeled [14C]-GSK3640254 as an oral suspension in treatment Period 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This will be an open-label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment period 1: Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC[0-inf]) in plasma following administration of IV dose of 14 Carbon [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate [14C]-GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: AUC(0-inf) in plasma following administration of oral dose of GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: AUC(0-inf) of total radioactivity in plasma following administration of IV dose of [14C]-GSK3640254</measure>
    <time_frame>Screening, Day-1, Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate total radioactivity in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: AUC(0-inf) in plasma following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: AUC(0-inf) of total radioactivity in plasma following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate total radioactivity in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: AUC from time zero (pre-dose) to last time of quantifiable concentration within a participant across all treatments (AUC[0-t]) in plasma following administration of IV dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate [14C]-GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: AUC (0-t) in plasma following administration of oral dose of GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: AUC(0-t) of total radioactivity in plasma following administration of IV dose of [14C]-GSK3640254</measure>
    <time_frame>Screening, Day-1, Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate total radioactivity in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: AUC (0-t) in plasma following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: AUC(0-t) of total radioactivity in plasma following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate total radioactivity in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Maximum observed concentration (Cmax) in plasma following administration of IV dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate [14C]-GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1:Cmax in plasma following administration of oral dose of GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Cmax of total radioactivity in plasma following administration of IV dose of [14C]-GSK3640254</measure>
    <time_frame>Screening, Day-1, Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate total radioactivity in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: Cmax in plasma following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: Cmax of total radioactivity in plasma following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate total radioactivity in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: Cmax of total radioactivity in blood following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (2, 4, 6, 8, 10 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate total radioactivity in blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1:Time of occurrence of Cmax (Tmax) in plasma following administration of IV dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate [14C]-GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1:Tmax in plasma following administration of oral dose of GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Tmax of total radioactivity in plasma following administration of IV dose of [14C]-GSK3640254</measure>
    <time_frame>Screening, Day-1, Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate total radioactivity in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: Tmax in plasma following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: Tmax of total radioactivity in plasma following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate total radioactivity in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: Tmax of total radioactivity in blood following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (2, 4, 6, 8, 10 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate total radioactivity in blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1:Terminal phase half-life (T1/2) in plasma following administration of IV dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate [14C]-GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: T1/2 in plasma following administration of oral dose of GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: T1/2 of total radioactivity in plasma following administration of IV dose of [14C]-GSK3640254</measure>
    <time_frame>Screening, Day-1, Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate total radioactivity in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: T1/2 in plasma following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate GSK3640254 in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: T1/2 of total radioactivity in plasma following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate total radioactivity in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Volume of distribution at steady state (Vss) following administration of IV dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis of [14C]-GSK3640254.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Total systemic clearance (CL) following administration of IV dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis of [14C]-GSK3640254.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Renal clearance (CLr) following administration of IV dose of GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose), 0-24 Hours, 24-48 Hours, 48-72 Hours, 72-96 Hours, 96-120 Hours, 120-144 Hours, 144-168 Hours</time_frame>
    <description>Urine samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: CLr following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose), 0-24 Hours, 24-48 Hours, 48-72 Hours, 72-96 Hours, 96-120 Hours, 120-144 Hours, 144-168 Hours</time_frame>
    <description>Urine samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Oral Clearance (CL/F) following oral dose of GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: CL/F following oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Apparent volume of distribution (Vz/F) following oral dose of GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: Vz/F following oral dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Absolute oral bioavailability (F) of GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Percentage of drug escaping first pass hepatic clearance (Fh) following administration of GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8,9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Percentage of drug absorbed (Fa) following administration of GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Percentage of drug escaping gut metabolism (Fg) following administration of GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 4.5, 5, 5.25, 6, 7, 8, 9, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose)</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Percentage of total radioactive dose in urine following administration of IV dose of [14C]-GSK3640254</measure>
    <time_frame>Day 1 (Pre-dose), 0-24 Hours, 24-48 Hours, 48-72 Hours 72 - 96 Hours, 96-120 Hours, 120-144 Hours, 144-168 Hours</time_frame>
    <description>Urine samples will be collected at the indicated time points to determine total radioactivity in urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: Percentage of the total radioactive dose in urine following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>0-24 Hours, 24-48 Hours, 48-72 Hours, 72-96 Hours, 96-120 Hours, 120-144 Hours, 144-168 Hours</time_frame>
    <description>Urine samples will be collected at the indicated time points to determine total radioactivity in urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 1: Percentage of total radioactive dose in feces following administration of IV dose of [14C]-GSK3640254</measure>
    <time_frame>0-24 Hours, 24-48 Hours, 48- 72 Hours, 72-96 Hours, 96-120 Hours, 120-144 Hours, 144-168 Hours.</time_frame>
    <description>Fecal samples will be collected at the indicated time points to determine total radioactivity in feces.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment period 2: Percentage of total radioactive dose in feces following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>0-24 Hours, 24-48 Hours, 48-72 Hours, 72-96 Hours, 96-120 Hours, 120-144 Hours, 144-168 Hours.</time_frame>
    <description>Fecal samples will be collected at the indicated time points to determine total radioactivity in feces.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants With Adverse Events (AEs) and Serious AEs (SAEs)</measure>
    <time_frame>Up to 50 days</time_frame>
    <description>AEs and SAEs will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal hematology, clinical chemistry and urinalysis parameters</measure>
    <time_frame>Day -1, Day 2 (36 hours), Day 5 , Day 8 and up to 50 days</time_frame>
    <description>Blood samples and urine samples will be collected for assessment of hematology, clinical chemistry and urine parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal 12-lead electrocardiogram (ECG)</measure>
    <time_frame>Up to 50 days</time_frame>
    <description>Single12-lead ECG will be recorded with the participant in a supine position. Number of participants with abnormal ECG findings will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal vital signs</measure>
    <time_frame>Up to 50 days</time_frame>
    <description>Number of participants with abnormal vital signs will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Period 2: Total radioactivity in blood to plasma following administration of oral dose of [14C]-GSK3640254</measure>
    <time_frame>2 Hours, 4 Hours, 6 Hours, 8 Hours, and 10 Hours</time_frame>
    <description>Blood samples will be collected at the indicated time points to evaluate total radioactivity following administration of oral dose of [14C]-GSK3640254.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>GSK3640254 tablet + [14C]-GSK3640254 IV/[14C] oral suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of GSK3640254 200 milligram (mg) (2Ã—100 mg) tablets with a moderate fat meal. Participants will then be administered a 100 microgram (mcg) dose (approximately 3.7 kilobecquerel; 100 nano Curie) of [14C]-GSK3640254 as an IV infusion for 1 hour on Day 1 in treatment Period 1, On Day 1 in treatment Period 2, participants will receive a single oral dose of 85 mg (approximately 3.15 megabecquerel; 85 micro Curie) [14C]-GSK3640254 administered as an oral suspension with a moderate fat meal. A wash out period of at least 13 days will be maintained between oral doses of treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3640254 Oral tablet</intervention_name>
    <description>GSK3640254 will be available as white film-coated round tablets to be administered via oral route with meal in the morning with 240 milliliter (mL) of water at room temperature.</description>
    <arm_group_label>GSK3640254 tablet + [14C]-GSK3640254 IV/[14C] oral suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-GSK3640254 intravenous infusion</intervention_name>
    <description>[14C]-GSK3640254 will be available as clear, colorless solution free from visible particulates to be administered via the IV route.</description>
    <arm_group_label>GSK3640254 tablet + [14C]-GSK3640254 IV/[14C] oral suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-GSK3640254 powder</intervention_name>
    <description>[14C]-GSK3640254 will be available as white powder to be reconstituted into a suspension with 25 mL of vehicle before dosing so as to administer 85 mg dose with meal in the morning.</description>
    <arm_group_label>GSK3640254 tablet + [14C]-GSK3640254 IV/[14C] oral suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 30 to 50 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination, laboratory tests, vital signs and ECG. A&#xD;
             participant with a clinical abnormality or laboratory parameter (i.e. outside the&#xD;
             reference range for the population being studied), which is not specifically listed in&#xD;
             the eligibility criteria, may be included only if the investigator agrees and&#xD;
             documents that the finding is unlikely to introduce additional risk factors and will&#xD;
             not interfere with the study procedures.&#xD;
&#xD;
          -  History of regular bowel movements (averaging one or more bowel movements per day).&#xD;
&#xD;
          -  Non-smoker, or ex-smoker who hasn't regularly smoked for the 6 months before&#xD;
             Screening.&#xD;
&#xD;
          -  Body weight of 50 kilograms (kg) and above, and body mass index (BMI) within the range&#xD;
             19.0 to 31.0 kg/square meter (m^2) (inclusive).&#xD;
&#xD;
          -  Male participants are eligible to participate if they agree to the following during&#xD;
             the study, including washout periods: Refrain from donating sperm and either a) be&#xD;
             abstinent from heterosexual intercourse as their preferred and usual lifestyle&#xD;
             (abstinent on a long term and persistent basis) and agree to remain abstinent or b)&#xD;
             Agree to use a male condom when having penile-vaginal intercourse with a woman of&#xD;
             childbearing potential unless vasectomized.&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones). Participants&#xD;
             with a history of cholecystectomy must be excluded.&#xD;
&#xD;
          -  Significant history of or current cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, or neurological disorders capable of&#xD;
             significantly altering the absorption, metabolism, or elimination of drugs;&#xD;
             constituting a risk when taking the study intervention; or interfering with the&#xD;
             interpretation of data.&#xD;
&#xD;
          -  Any clinically relevant abnormality identified at the Screening medical assessment&#xD;
             (physical examination/medical history) clinical laboratory tests, or 12-lead ECG.&#xD;
&#xD;
          -  Current episode, recent history, or chronic history of diarrhea.&#xD;
&#xD;
          -  Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or&#xD;
             squamous epithelial carcinomas of the skin that have been resected with no evidence of&#xD;
             metastatic disease for 3 years.&#xD;
&#xD;
          -  Any history of significant underlying psychiatric disorder, including, but not limited&#xD;
             to, schizophrenia, bipolar disorder with or without psychotic symptoms, other&#xD;
             psychotic disorders, or schizotypal (personality) disorder.&#xD;
&#xD;
          -  Any history of major depressive disorder with or without suicidal features, or anxiety&#xD;
             disorders that required medical intervention (pharmacologic or not) such as&#xD;
             hospitalization or other inpatient treatment and/or chronic (&gt;6 months) outpatient&#xD;
             treatment. Participants with other conditions such as adjustment disorder or dysthymia&#xD;
             that have required shorter term medical therapy (&lt;6 months) without inpatient&#xD;
             treatment and are currently well-controlled clinically or resolved may be considered&#xD;
             for entry after discussion and agreement with the ViiV Healthcare (VH)/GlaxoSmithKline&#xD;
             (GSK) Medical Monitor.&#xD;
&#xD;
          -  Any pre-existing physical or other psychiatric condition (including alcohol or drug&#xD;
             abuse), which, in the opinion of the investigator (with or without psychiatric&#xD;
             evaluation), could interfere with the participant's ability to comply with the dosing&#xD;
             schedule and protocol.&#xD;
&#xD;
          -  Regular use of known drugs of abuse or history of drug abuse or dependence within 6&#xD;
             months of the study.&#xD;
&#xD;
          -  Regular alcohol consumption within 6 months prior to the study defined as an average&#xD;
             weekly intake of &gt;21 units. One unit is equivalent to 8 grams of alcohol: a glass&#xD;
             (equivalent to [~]240 mL) of beer, 1 small glass (~100 mL) of wine or 1 (~25 mL)&#xD;
             measure of spirits.&#xD;
&#xD;
          -  History of or regular use of tobacco- or nicotine-containing products in the 3 months&#xD;
             prior to Screening.&#xD;
&#xD;
          -  Medical history of cardiac arrhythmias, prior myocardial infarction in the past 3&#xD;
             months, or cardiac disease or a family or personal history of long QT syndrome.&#xD;
&#xD;
          -  QT duration corrected for heart rate by Fridericia's formula (QTcF) &gt;450 milliseconds&#xD;
             (msec).&#xD;
&#xD;
          -  At Screening or prior to the first dose, a supine blood pressure (BP) that is&#xD;
             persistently higher than 140/90 millimeters of mercury (mmHg).&#xD;
&#xD;
          -  At Screening or prior to the first dose, a supine mean heart rate (HR) outside the&#xD;
             range of 50 to 100 beats per minute (bpm). A heart rate from 100 to 110 bpm can be&#xD;
             rechecked by ECG or vital signs within 30 minutes to verify eligibility.&#xD;
&#xD;
          -  A participant with known or suspected active COVID-19 infection OR contact with an&#xD;
             individual with known COVID-19, within 14 days of study enrollment.&#xD;
&#xD;
          -  Past or intended use of over-the-counter or prescription medication, including&#xD;
             analgesics (example [e.g], paracetamol), herbal medications, or grapefruit and Seville&#xD;
             orange juices within 14 days prior to the first dose of study intervention until&#xD;
             completion of the follow-up visit unless approved by the Investigator in conjunction&#xD;
             with a VH/GSK Medical monitor.&#xD;
&#xD;
          -  Treatment with any vaccine within 30 days prior to receiving study intervention.&#xD;
&#xD;
          -  Current enrollment in a clinical trial; recent participation in a clinical trial and&#xD;
             has received an investigational product within 3 months before the first dose in the&#xD;
             current study.&#xD;
&#xD;
          -  Exposure to more than 4 new chemical entities within 12 months before the first dose&#xD;
             in the current study.&#xD;
&#xD;
          -  Participation in a clinical trial involving administration of 14C-labelled compound(s)&#xD;
             within the last 12 months. A participant's previous effective dose will be reviewed by&#xD;
             the medical investigator to ensure there is no risk of contamination/carryover into&#xD;
             the current study.&#xD;
&#xD;
          -  Received a total body radiation dose of greater than 10.0 millisievert (mSv) (upper&#xD;
             limit of International Commission on Radiological Protection [ICRP] category II) or&#xD;
             exposure to significant radiation (e.g., serial x-ray or computed tomography [CT]&#xD;
             scans, barium meal, etc.) in the 3 years before this study.&#xD;
&#xD;
          -  Alanine transaminase (ALT) &gt;=1.5 times upper limit of normal (ULN). A single repeat of&#xD;
             ALT is allowed within a single Screening period to determine eligibility.&#xD;
&#xD;
          -  Bilirubin &gt;=1.5 times ULN (isolated bilirubin &gt;=1.5 times ULN is acceptable if&#xD;
             bilirubin is fractionated and direct bilirubin &lt;35 percent (%). A single repeat of any&#xD;
             laboratory abnormality is allowed within a single Screening period to determine&#xD;
             eligibility.&#xD;
&#xD;
          -  Presence of Hepatitis B surface antigen (HBsAg) at Screening or positive Hepatitis C&#xD;
             antibody test result at Screening or within 3 months before the first dose of study&#xD;
             intervention and positive on reflex to hepatitis C ribonucleic acid (RNA).&#xD;
&#xD;
          -  Positive HIV-1 and -2 antigen/antibody immunoassay at Screening.&#xD;
&#xD;
          -  Any positive (abnormal) response confirmed by the investigator or qualified&#xD;
             designee-administered Columbia-Suicide Severity Rating Scale (C-SSRS).&#xD;
&#xD;
          -  Any Grade 2 to 4 laboratory abnormality at Screening, with the exception of creatine&#xD;
             phosphokinase (CPK) and lipid abnormalities (e.g., total cholesterol, triglycerides),&#xD;
             and ALT (described above), will exclude a participant from the study unless the&#xD;
             investigator can provide a compelling explanation for the laboratory result(s) and has&#xD;
             the assent of the sponsor. A single repeat of any laboratory abnormality (other than a&#xD;
             viral Screening test for HIV-1/2, hepatitis B Virus [HBV], or hepatitis C Virus [HCV])&#xD;
             is allowed within a single Screening period to determine eligibility.&#xD;
&#xD;
          -  Any significant arrhythmia or ECG finding (e.g., prior myocardial infarction in the&#xD;
             past 3 months, symptomatic bradycardia, non-sustained or sustained atrial arrhythmias,&#xD;
             non-sustained or sustained ventricular tachycardia, second-degree atrioventricular&#xD;
             block Mobitz Type II, third-degree atrioventricular block, complete heart block, or&#xD;
             conduction abnormality) which, in the opinion of the investigator or VH/GSK Medical&#xD;
             Monitor, will interfere with the safety for the individual participant. Any acute&#xD;
             laboratory abnormality at Screening which, in the opinion of the investigator, should&#xD;
             preclude participation in the study of an investigational compound.&#xD;
&#xD;
          -  Has had an occupation which requires monitoring for radiation exposure, nuclear&#xD;
             medicine procedures, or excessive x-rays within the past 3 years.&#xD;
&#xD;
          -  Loss of more than 400 mL blood during the 3 months before Screening, e.g., as a blood&#xD;
             donor, or plan to donate blood or blood products in the 3 months after the end of the&#xD;
             trial.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol,&#xD;
             including the use of the string bile collection device.&#xD;
&#xD;
          -  History of sensitivity to GSK3640254, or their components thereof, or a history of&#xD;
             drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor,&#xD;
             contraindicates their participation.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male participants will be part of this study.</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus (HIV)</keyword>
  <keyword>GSK3640254</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Radiolabeled</keyword>
  <keyword>Mass balance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

